PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical

TOKYO, Japan, 31 May 2023: – PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced a milestone achievement of a clinical development conducted by Ohara Pharmaceutical Co., Ltd., a Japanese pharmaceutical company that discovers and develops orphan drugs and generic drugs, based on their licensing agreement related to a new compound PRI-724/OP-724.

Read Full Press Release

Scroll to top